Tag: $Mirati Theraoeutics

Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.